)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Faes Farma
Faes Farma (FAE) investor relations material
Faes Farma Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary29 Oct, 2026
Executive summary
9M 2026 revenue rose 24% to €563.5M; EBITDA increased 17% to €124.4M, or 20% excluding €3.2M of SIFI and Edol restructuring costs.
Acquisitions, international direct-market growth and ophthalmology expansion diversified revenue; Japan bilastine loss of exclusivity weighed on licensing.
Financial highlights
Net revenue increased 25% to €551.9M; gross profit rose 27% to €380.6M and operating profit increased 7% to €94.5M.
EBITDA reached €124.4M, up 17%, or 20% excluding €3.2M of SIFI and Edol restructuring costs.
Consolidated net profit was €74.3M, up 1%; parent-attributable profit was €74.1M, up 1%.
Staff costs rose 41% to €126.3M, reflecting expanded scope, restructuring and strategic hiring; other operating expenses increased 24%.
Financial expenses increased to €7.2M from €1.1M; depreciation, amortisation and impairment rose 60% to €29.9M.
Outlook and guidance
FY26 guidance reaffirmed: revenue growth of 17%–19%, EBITDA growth of 28%–31%, and net debt/EBITDA below 2x; EBITDA guidance includes remaining Derio costs.
Growth drivers include strategic-market expansion, full SIFI and Edol integration, commercial synergies and efficiencies following the Derio move.
Q4 sales growth expected to slow against a comparison period including SIFI and Edol; EBITDA expected to accelerate with lower one-off costs and stronger existing businesses, particularly SIFI.
FY26 pro forma growth estimated at ~10% excluding Japan bilastine impact; quantitative FY27 guidance deferred to full-year results. Japan’s impact is expected to ease in FY27.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Faes Farma
- Revenue up 27%, EBITDA up 24%, net profit up 9%, ophthalmology now 16% of revenue.FAE
Q2 2026 - Revenue up 15.5% to €454M, with EBITDA up 3% and strategic integration supporting growth.FAEQ3 2025
- Revenue up 31% and net profit up 9%, driven by international and ophthalmology growth.FAEQ1 2026
- 23% revenue growth, major acquisitions, and strong 2026 outlook driven by integration.FAEQ4 2025
- Revenue up 12.3% to €307.4M, with strong pharma and animal health growth; outlook positive.FAEQ2 2025
- Strong revenue and profit growth in 9M 2024, with robust Pharma performance and positive outlook.FAEQ3 2024
- Double-digit growth in sales and profit, strong cash, and higher dividends in H1 2024.FAEQ2 2024
- €270M acquisition expands ophthalmology, rare disease reach, and delivers immediate EPS accretion.FAEM&A Announcement
- Faes Farma aims to double revenues by 2030 through global expansion, M&A, and innovation.FAECMD 2025
Next Faes Farma earnings date
Q4 202625 Feb, 2027
Faes Farma
Next Faes Farma earnings date
Q4 202625 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Faes Farma S.A. is a pharmaceutical company based in Spain that focuses on the development, manufacture, and commercialization of a range of pharmaceutical products and raw materials. The company offers prescription medications, generic drugs, over-the-counter (OTC) products, food supplements, and personal care treatments. Faes Farma also has a presence in animal nutrition and healthcare sectors. It operates on a global scale, exporting products to various international market. The company is headquartered in Leioa, Spain, and its shares are listed on the Madrid Stock Exchange.